Drugs

Metformin Can Improve Surgical Recovery

Metformin, a commonly-prescribed diabetes drug, may have other benefits, researchers say. A study found that metformin use in patients with type 2 diabetes is associated with a reduced risk of rehospitalization and death following surgery. Read more

Start Combination Therapy Earlier, ADA Says

Metformin is the typical first-line treatment for people with type 2 diabetes, but the ADA suggests early combination therapy with other medications should be used in patients with type 2 diabetes and chronic kidney disease or cardiovascular disease. Read more

More Evidence for Heart Benefits of Empagliflozin

Studies of diabetes drugs empagliflozin and dapagliflozin, both in the SGLT-2 inhibitor class, have shown they help reduce cardiovascular risk for diabetes patients. Now, researchers have found that empagliflozin is beneficial for the heart in people without diabetes as well. Read more

Once-Weekly Semaglutide May Assist with Weight Loss

The diabetes drug semaglutide, administered once-weekly subcutaneously and used in conjunction with lifestyle modifications, helped people with overweight or obesity achieve sustained, significant reductions in body weight. Read more

Diabetes Pharma Company Seeks to Reach More Young People with Type 1

Eli Lilly is expanding its existing type 1 diabetes partnership with Life for a Child, with the goal of supporting more than six times as many children in the next 10 years. Lilly plans to expand care to 150,000 young people with diabetes over the next decade, providing free medicine and equipment like reusable pens […]

Add-on Therapy Can Reduce Insulin Use for Type 2 Patients

Insulin is the mainstay treatment for patients with type 2 diabetes who also have beta-cell failure; however, some insulin regimens can be complicated to manage and may increase the risk of hypoglycemia. Now, researchers say that a simple add-on therapy with the GLP-1 Agonist medication albiglutide can reduce insulin use for patients with type 2 […]

Adding the Right Meds Early Can Reduce Heart Risks

High blood glucose levels can damage the heart’s nerves and blood vessels. This contributes to the development of heart diseases and eventual heart attacks. However, new research shows that starting patients on medication to prevent cardiovascular diseases when they are first diagnosed with diabetes can help reduce the risk. Read more

Daily Pill Could Help Optimize Insulin Use

New studies have investigated a once-daily pill that can optimize insulin therapy and reduce HbA1c among adults with type 1 diabetes. The pill, a novel liver-selective glucokinase activator, also known as TTP399, showed superior A1c reduction compared to placebo. Read more

How SGLT2 Inhibitors Affect Risk of Death

A recent study that aimed to review and assess all the current evidence regarding SGLT2 inhibitors and their impact on death from all causes in diabetes patients found that overall, this class of diabetes drug was associated with a reduction in all-cause mortality. Read more

Effect of Empagliflozin on Kidney Disease

Empagliflozin (sold under the brand name Jardiance) may reduce major adverse kidney events in some type 2 diabetes patients better than other medications, researchers say. The study used U.S. Department of Veterans Affairs (VA) data to assess the effectiveness of empagliflozin versus other antihyperglycemic drugs. Read more

Immunosuppressive Medication Shows Potential for Type 1 Treatment

Golimumab is a human antibody that is used as an immunosuppressive drug (brand name Simponi) and is approved for the treatment of several autoimmune conditions, including ulcerative colitis. Researchers investigated whether golimumab could preserve beta-cell function in young people newly diagnosed with type 1 diabetes. Read more

Could Diabetes Drug Sitagliptin Help Treat COVID-19?

Some research has suggested that inhibiting the protein DPP-4, which is produced by the human body, could provide benefit to patients infected with COVID-19. Sitagliptin is a diabetes drug in the DPP-4 inhibitor class that has also shown anti-inflammatory and immunoregulatory effects. Researchers investigated whether sitagliptin could help treat hospitalized COVID patients with type 2 […]

Assessing Metformin in the Diabetes Landscape

Metformin is the standard first medication treatment of choice for people newly diagnosed with type 2 diabetes. A group of researchers decided to examine whether metformin, which this year celebrates its 63rd anniversary as a type 2 diabetes treatment, continues to earn its spot as a key member of the diabetes medication “All-Star Team.” Read more

The Consequences of Polypharmacy in the Elderly

Many older patients with type 2 diabetes deal with polypharmacy — taking multiple medications for their diabetes and other conditions. Polypharmacy can be burdensome in various ways, including multiple side effects of the various medications. Researchers investigated whether the use of polypharmacy put elderly patients at increased risk for hospitalization, falls, and death from all […]

Sotagliflozin and Chronic Kidney Disease

A recent phase 3 clinical trial on the diabetes drug sotagliflozin, an SGLT2 inhibitor, found it had favorable results for people living with severe renal impairment / chronic kidney disease.  Read more

How Do Metformin and Exercise Affect Glucose?

People who have prediabetes or type 2 diabetes are usually urged to make lifestyle modifications, including diet, exercise, and weight control as the first form of treatment; metformin is typically the first drug prescribed when lifestyle interventions are insufficient. A recent study examined how the interface of physical activity and metformin affects post-meal glucose in […]

Drug Combo Could Help Patients Who No Longer Respond to Metformin

Metformin is the first-line drug treatment for type 2 diabetes, but in some patients, the drug’s effectiveness can decline over time. A clinical trial has found that a combination of two newer diabetes drugs, exenatide and dapagliflozin, is effective in patients whose blood glucose levels did not respond to metformin. Read more

Can Semaglutide Add Years to Your Life?

The diabetes drugs known as the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class have demonstrated clear benefit for cardiovascular disease associated with diabetes. Researchers wanted to take a closer look at one GLP-1 RA medication, semaglutide, and determine how many years can be added to a patient’s life with this drug’s addition. Read more

Can DPP-4 Inhibitors Increase Pneumonia Risk?

Patients with diabetes have a higher risk for developing pneumonia, including viral pneumonia. Since the DPP-4 protein plays a role in infection for some coronaviruses, researchers wanted to study whether using DPP-4 inhibitor diabetes drugs could increase risk for pneumonia. Read more

Which Diabetes Drug Class is Better for the Heart?

Uncontrolled or poorly controlled type 2 diabetes is linked to many serious consequences, including death, heart failure, stroke, and myocardial infarction. A recent study compared the use of two antidiabetic medications, SGLT-2 inhibitors (such as Invokana and Jardiance) and GLP-1 receptor agonists (such as Bydureon and Farxiga), to see if one offered better cardiovascular protection. […]